Pharmaceuticals, Biotechnology & Life Sciences

Coen Steven P. sells 2,403 Ginkgo Bioworks shares at $15, signaling steady insider confidence while the company scales its synthetic‑biology platform and eyes new funding rounds.

Illumina CEO Thaysen Jacob sells 1,303 shares—minor portfolio tweak, not a red flag. Understand why insiders trade and focus on Illumina’s strong growth.

Liquidia insider Bloch sells 235,000 shares amid a patent‑infringement ruling, hinting at portfolio rebalancing rather than a crash.

Arbutus Biopharma insider selling signals a strategic shift: CEO, CFO, and top execs sell shares, raising questions about the stock’s future and the impact on investor sentiment.

VAXCYTE insiders, led by Wassil Jim, buy low and sell high—showing confidence in upcoming VAX‑31 data and a new $500M capital raise.

Insider option buys at zero cost signal confidence in Humacyte’s future – investors may spot upside as execs bet on the bio‑tissue platform’s growth.

Twist Bioscience’s insider sales show routine liquidity moves, not a warning—focus on its biotech pipeline, earnings outlook, and market dynamics.

Moderna CFO Mock’s latest insider trade: a fresh buy of 1,454 shares signals confidence amid a 52‑week high, while routine sells show normal liquidity. Discover how insider activity reflects management’s bullish stance on the mRNA leader.

CEO Aslan Fred sells 23,463 Artiva Biotherapeutics shares at $7.20, a routine tax‑cover move that shows stable insider activity and modest impact on stock.

George Milne’s October 5 sale of 30,000 Amylyx shares at $27.70 shows routine insider profit‑taking amid a 19% yearly rise, indicating stable confidence in the ALS biotech’s pipeline.